RA Capital Management 13F holdings, Q1 2021
Holdings as of March 31, 2021 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 82 US equity positions worth $6.6bn in its Q1 2021 13F filing. The largest position was ASND at 12.5% of the reported book, followed by NVAX and VOR. Against the Q4 2020 filing, it opened 7 new positions, added to 8 and reduced 9 among the top 50 holdings.
What did RA Capital Management own in Q1 2021? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2020 |
|---|---|---|---|---|---|---|---|
| 1 | ASND ASCENDIS PHARMA A/S | Healthcare | 12.5% | $826.4m | 6,412,228 | 9% | added |
| 2 | NVAX NOVAVAX INC | Healthcare | 8.2% | $544.3m | 3,002,087 | -21% | reduced |
| 3 | VOR VOR BIOPHARMA INC | 7.2% | $479.3m | 11,120,973 | – | new | |
| 4 | AVIR ATEA PHARMACEUTICALS INC | Healthcare | 5.0% | $331.5m | 5,368,451 | 0% | held |
| 5 | FORMA THERAPEUTICS HLDGS INC | 3.8% | $252.5m | 9,011,651 | 0% | held | |
| 6 | TGTX TG THERAPEUTICS INC | Healthcare | 3.4% | $223.5m | 4,636,146 | -47% | reduced |
| 7 | NKTX NKARTA INC | Healthcare | 2.8% | $184.4m | 5,605,129 | 0% | held |
| 8 | CHEMOCENTRYX INC | 2.7% | $182.3m | 3,556,810 | -26% | reduced | |
| 9 | MGNX MACROGENICS INC | Healthcare | 2.4% | $157.1m | 4,933,594 | 13% | added |
| 10 | ITEOS THERAPEUTICS INC | 2.3% | $151.0m | 4,417,258 | 0% | held | |
| 11 | IMMUNOGEN INC | 2.2% | $149.2m | 18,417,458 | 0% | held | |
| 12 | TVTX TRAVERE THERAPEUTICS INC | Healthcare | 2.1% | $140.2m | 5,614,428 | 23% | added |
| 13 | TIL INSTIL BIO INC | 1.8% | $122.2m | 4,870,793 | – | new | |
| 14 | PHAT PHATHOM PHARMACEUTICALS INC | 1.8% | $117.0m | 3,115,008 | -19% | reduced | |
| 15 | 89BIO INC | 1.7% | $112.2m | 4,736,214 | 0% | held | |
| 16 | KINNATE BIOPHARMA INC | 1.7% | $112.0m | 3,593,052 | 0% | held | |
| 17 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 1.6% | $103.6m | 4,871,067 | 17% | added |
| 18 | ZOGENIX INC | 1.6% | $103.1m | 5,283,976 | -1% | reduced | |
| 19 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 1.4% | $93.7m | 1,655,447 | 0% | held |
| 20 | RCKT ROCKET PHARMACEUTICALS INC COM | Healthcare | 1.4% | $93.5m | 2,107,149 | -1% | reduced |
| 21 | ADVERUM BIOTECHNOLOGIES INC | 1.4% | $92.3m | 9,365,833 | -1% | reduced | |
| 22 | EWTX EDGEWISE THERAPEUTICS INC | 1.3% | $84.9m | 2,613,623 | – | new | |
| 23 | CRIS CURIS INC | Healthcare | 1.2% | $80.8m | 7,140,091 | -7% | reduced |
| 24 | BOLT BOLT BIOTHERAPEUTICS INC | 1.2% | $78.3m | 2,378,325 | – | new | |
| 25 | PCVX VAXCYTE INC | Healthcare | 1.2% | $76.3m | 3,865,808 | 4% | added |
| 26 | MCRB SERES THERAPEUTICS INC | Healthcare | 1.1% | $76.1m | 3,694,193 | – | new |
| 27 | SPRY SILVERBACK THERAPEUTICS INC | Healthcare | 1.1% | $76.0m | 1,742,186 | 0% | held |
| 28 | IGM BIOSCIENCES INC | 1.1% | $75.4m | 982,723 | 0% | held | |
| 29 | KALA PHARMACEUTICALS INC | 1.1% | $73.3m | 10,874,613 | 0% | held | |
| 30 | OLMA OLEMA PHARMACEUTICALS INC | Healthcare | 1.1% | $71.3m | 2,150,404 | 0% | held |
| 31 | ORCHARD THERAPEUTICS PLC | 1.0% | $69.2m | 12,315,213 | 0% | held | |
| 32 | SLDB SOLID BIOSCIENCES INC | 1.0% | $68.4m | 12,367,873 | 24% | added | |
| 33 | DSGN DESIGN THERAPEUTICS INC | Healthcare | 1.0% | $65.4m | 2,186,636 | – | new |
| 34 | BLACK DIAMOND THERAPEUTICS INC | 0.9% | $62.8m | 2,589,904 | 0% | held | |
| 35 | TRILLIUM THERAPEUTICS INC | 0.9% | $56.8m | 5,290,481 | 0% | held | |
| 36 | PMVP PMV PHARMACEUTICALS INC | 0.8% | $56.3m | 1,710,265 | 0% | held | |
| 37 | CNTB CONNECT BIOPHARMA HLDGS LTD | 0.8% | $55.3m | 2,991,208 | – | new | |
| 38 | CNST CONSTELLATION PHARMCETICLS INC | 0.8% | $52.4m | 2,238,536 | 21% | added | |
| 39 | CCCC C4 THERAPEUTICS INC | Healthcare | 0.8% | $51.0m | 1,377,569 | 0% | held |
| 40 | STRO SUTRO BIOPHARMA INC | Healthcare | 0.7% | $48.2m | 2,118,212 | 0% | held |
| 41 | GERN GERON CORP | Healthcare | 0.7% | $47.6m | 30,126,299 | 0% | held |
| 42 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 0.7% | $43.6m | 7,775,207 | 0% | held |
| 43 | DYN DYNE THERAPEUTICS INC | Healthcare | 0.7% | $43.6m | 2,805,045 | 0% | held |
| 44 | VRNA VERONA PHARMA PLC | 0.6% | $42.6m | 5,100,000 | 0% | held | |
| 45 | ARDX ARDELYX INC | Healthcare | 0.6% | $40.2m | 6,077,294 | -1% | reduced |
| 46 | INOZYME PHARMA INC | 0.6% | $39.7m | 2,003,653 | 0% | held | |
| 47 | SATSUMA PHARMACEUTICALS INC | 0.5% | $35.0m | 5,914,252 | 26% | added | |
| 48 | RLAY RELAY THERAPEUTICS INC | Healthcare | 0.5% | $34.6m | 1,000,000 | 0% | held |
| 49 | AKOUOS INC | 0.5% | $31.6m | 2,281,249 | 0% | held | |
| 50 | CEREVEL THERAPEUTICS HLDNG INC | 0.5% | $30.2m | 2,200,000 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.